

# Eric Aboagye

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8271174/publications.pdf>

Version: 2024-02-01

182  
papers

8,471  
citations

71102

41  
h-index

51608

86  
g-index

188  
all docs

188  
docs citations

188  
times ranked

12982  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the welfare and use of animals in cancer research. <i>British Journal of Cancer</i> , 2010, 102, 1555-1577.	6.4	1,167
2	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
3	Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress. <i>Cancer Cell</i> , 2015, 27, 57-71.	16.8	596
4	Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. <i>Cancer Research</i> , 1999, 59, 80-4.	0.9	423
5	Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with $^{3\text{-deoxy-}^3\text{-[18F]fluorothymidine}}$ positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1339-1347.	6.4	252
6	$3\text{'-deoxy-}3\text{'-[18F]fluorothymidine}$ as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. <i>Cancer Research</i> , 2003, 63, 3791-8.	0.9	201
7	Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies. <i>Journal of the National Cancer Institute</i> , 2006, 98, 580-598.	6.3	189
8	Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. <i>Cancer &amp; Metabolism</i> , 2016, 4, 6.	5.0	186
9	Quantification of Cellular Proliferation in Tumor and Normal Tissues of Patients with Breast Cancer by $^{[18F]Fluorothymidine}$ -Positron Emission Tomography Imaging: Evaluation of Analytical Methods. <i>Cancer Research</i> , 2005, 65, 10104-10112.	0.9	175
10	Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [ $^{18}$ F]-labeled isatin sulfonamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16375-16380.	7.1	157
11	Multiplexed imaging for diagnosis and therapy. <i>Nature Biomedical Engineering</i> , 2017, 1, 697-713.	22.5	133
12	A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. <i>Nature Communications</i> , 2019, 10, 764.	12.8	130
13	Design, Synthesis, and Biological Characterization of a Caspase 3/7 Selective Isatin Labeled with $2\text{-[}^{18}\text{F]fluoroethylazide}$ . <i>Journal of Medicinal Chemistry</i> , 2008, 51, 8057-8067.	6.4	126
14	Molecular mechanisms of hypoxia in cancer. <i>Clinical and Translational Imaging</i> , 2017, 5, 225-253.	2.1	119
15	Use of $^{[11C]Choline}$ PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression. <i>Clinical Cancer Research</i> , 2011, 17, 7673-7683.	7.0	107
16	In vivo evaluation of $^{[18F]fluoroetamidazole}$ as a new marker for imaging tumour hypoxia with positron emission tomography. <i>British Journal of Cancer</i> , 2004, 90, 2232-2242.	6.4	93
17	ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1156-1166.	4.1	93
18	Nm23-transfected MDA-mB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: A31P nuclear magnetic resonance study in vivo and in vitro. <i>Magnetic Resonance in Medicine</i> , 1999, 41, 897-903.	3.0	91

#	ARTICLE	IF	CITATIONS
19	Redistribution of Nucleoside Transporters to the Cell Membrane Provides a Novel Approach for Imaging Thymidylate Synthase Inhibition by Positron Emission Tomography. <i>Cancer Research</i> , 2006, 66, 8558-8564.	0.9	87
20	Alterations of Choline Phospholipid Metabolism in Endometrial Cancer Are Caused by Choline Kinase Alpha Overexpression and a Hyperactivated Deacylation Pathway. <i>Cancer Research</i> , 2014, 74, 6867-6877.	0.9	87
21	<sup>18</sup> F-ICMT-11, a Caspase-3-Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1551-1556.	5.0	83
22	Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. <i>Lancet</i> , The, 2000, 355, 2125-2131.	13.7	78
23	Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications. <i>ChemMedChem</i> , 2018, 13, 2466-2478.	3.2	77
24	Pharmacokinetic Evaluation of N-[2-(Dimethylamino)Ethyl]Acridine-4-Carboxamide in Patients by Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2001, 19, 1421-1429.	1.6	76
25	Monitoring Predominantly Cytostatic Treatment Response with <sup>18</sup> F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 97S-105S.	5.0	75
26	Gold Nanostar Substrates for Metal-Enhanced Fluorescence through the First and Second Near-Infrared Windows. <i>Chemistry of Materials</i> , 2017, 29, 6916-6926.	6.7	72
27	In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with <sup>3</sup> -Deoxy- <sup>3</sup> -[ <sup>18</sup> F]Fluorothymidine Positron Emission Tomography. <i>Cancer Research</i> , 2006, 66, 7621-7629.	0.9	68
28	<sup>68</sup> Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. <i>Radiotherapy and Oncology</i> , 2019, 141, 108-115.	0.6	62
29	Multi-modal Learning from Unpaired Images: Application to Multi-organ Segmentation in CT and MRI. , 2018, , .		61
30	A bioorthogonal <sup>68</sup> Ga-labelling strategy for rapid in vivo imaging. <i>Chemical Communications</i> , 2014, 50, 9557-9560.	4.1	60
31	Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. <i>EJNMMI Research</i> , 2015, 5, 30.	2.5	60
32	Discovery of pre-therapy 2-deoxy-2- <sup>18</sup> F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 455-466.	6.4	59
33	Evaluation of Deuterated <sup>18</sup> F- and <sup>11</sup> C-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2012, 18, 1063-1072.	7.0	58
34	Altered Tissue <sup>3</sup> -Deoxy- <sup>3</sup> -[ <sup>18</sup> F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2009, 15, 6649-6657.	7.0	52
35	Reproducibility of [ <sup>11</sup> C]Choline-Positron Emission Tomography and Effect of Trastuzumab. <i>Clinical Cancer Research</i> , 2010, 16, 4236-4245.	7.0	52
36	Apparent Diffusion Coefficient of Normal Abdominal Organs and Bone Marrow From Whole-Body DWI at 1.5 T: The Effect of Sex and Age. <i>American Journal of Roentgenology</i> , 2015, 205, 242-250.	2.2	52

#	ARTICLE	IF	CITATIONS
37	Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. <i>Frontiers in Oncology</i> , 2016, 6, 44.	2.8	49
38	[11C]Choline Positron Emission Tomography in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5503-5510.	7.0	48
39	Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3 Selective Molecular Imaging. <i>Clinical Cancer Research</i> , 2013, 19, 3914-3924.	7.0	48
40	Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. <i>British Journal of Cancer</i> , 2002, 87, 783-789.	6.4	46
41	Synthesis and in vitro evaluation of [18F]fluoroethyl triazole labelled [Tyr <sup>3</sup> ]octreotate analogues using click chemistry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3122-3127.	2.2	44
42	Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3112-3121.	4.1	43
43	Targeting Somatostatin Receptors: Preclinical Evaluation of Novel <sup>18</sup> F-Fluoroethyltriazole-Tyr <sup>3</sup> -Octreotate Analogs for PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1441-1448.	5.0	41
44	A Novel Radiotracer to Image Glycogen Metabolism in Tumors by Positron Emission Tomography. <i>Cancer Research</i> , 2014, 74, 1319-1328.	0.9	38
45	[18F]Fluoromethyl-[1,2-2H <sub>4</sub> ]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography. <i>Cancer Research</i> , 2009, 69, 7721-7728.	0.9	37
46	Radiosynthesis and pre-clinical evaluation of [18F]fluoro-[1,2-2H <sub>4</sub> ]choline. <i>Nuclear Medicine and Biology</i> , 2011, 38, 39-51.	0.6	37
47	Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. <i>Cancer Research</i> , 1998, 58, 4075-8.	0.9	37
48	The Physiological Environment in Cancer Vascularization, Invasion and Metastasis. <i>Novartis Foundation Symposium</i> , 2008, 240, 23-45.	1.1	36
49	The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death. <i>British Journal of Cancer</i> , 2018, 119, 1278-1287.	6.4	36
50	Detection of tumor response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. <i>Cancer Research</i> , 1998, 58, 1063-7.	0.9	36
51	Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. <i>Cancer Research</i> , 2001, 61, 4937-41.	0.9	36
52	Imaging Pharmacodynamics of the Folate Receptor-Targeted Thymidylate Synthase Inhibitor BGC 945. <i>Cancer Research</i> , 2008, 68, 3827-3834.	0.9	35
53	New Frontiers in the Design and Synthesis of Imaging Probes for PET Oncology: Current Challenges and Future Directions. <i>Molecular Imaging and Biology</i> , 2012, 14, 653-666.	2.6	35
54	Clinical Translation of a Click-Labeled <sup>18</sup> F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1207-1213.	5.0	35

#	ARTICLE	IF	CITATIONS
55	Significant metal enhanced fluorescence of Ag <sub>2</sub> S quantum dots in the second near-infrared window. <i>Nanoscale</i> , 2016, 8, 12869-12873.	5.6	35
56	Clinical translation of [ <sup>18</sup> F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2285-2299.	6.4	35
57	Use of positron emission tomography in anticancer drug development. <i>Investigational New Drugs</i> , 2003, 21, 169-181.	2.6	33
58	Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells. <i>British Journal of Cancer</i> , 2020, 122, 1298-1308.	6.4	32
59	The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. <i>Oncotarget</i> , 2016, 7, 37103-37120.	1.8	32
60	Fully automatic, multiorgan segmentation in normal whole body magnetic resonance imaging (MRI), using classification forests (CFs), convolutional neural networks (CNNs), and a multi-atlas (MA) approach. <i>Medical Physics</i> , 2017, 44, 5210-5220.	3.0	31
61	Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 512-521.	6.4	31
62	Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6945-6949.	2.2	30
63	Fluorescence enhancement from single gold nanostars: towards ultra-bright emission in the first and second near-infrared biological windows. <i>Nanoscale</i> , 2018, 10, 15854-15864.	5.6	30
64	Towards multiplexed near-infrared cellular imaging using gold nanostar arrays with tunable fluorescence enhancement. <i>Nanoscale</i> , 2019, 11, 2079-2088.	5.6	30
65	Real-time measurements of cellular oxygen consumption, pH, and energy metabolism using nuclear magnetic resonance spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2001, 45, 749-755.	3.0	29
66	Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. <i>PLoS ONE</i> , 2014, 9, e91694.	2.5	29
67	Kinetic filtering of [ <sup>18</sup> F]Fluorothymidine in positron emission tomography studies. <i>Physics in Medicine and Biology</i> , 2010, 55, 695-709.	3.0	27
68	Development and Evaluation of an <sup>18</sup> F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression. <i>Molecular Pharmaceutics</i> , 2019, 16, 2106-2117.	4.6	26
69	Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival. <i>Radiologia Medica</i> , 2020, 125, 770-776.	7.7	26
70	Choline Kinase Alpha (CHK1±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 323-333.	4.1	25
71	Snapshot imprinting: rapid identification of cancer cell surface proteins and epitopes using molecularly imprinted polymers. <i>Nano Today</i> , 2021, 41, 101304.	11.9	24
72	Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development. <i>Molecular Imaging and Biology</i> , 2005, 7, 53-58.	2.6	23

#	ARTICLE	IF	CITATIONS
73	Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia. Dalton Transactions, 2016, 45, 144-155.	3.3	23
74	Preclinical evaluation of a CXCR4-specific 68Ga-labelled TN14003 derivative for cancer PET imaging. Bioorganic and Medicinal Chemistry, 2014, 22, 796-803.	3.0	22
75	Preclinical Evaluation of 3- <sup>18</sup> F-Fluoro-2,2-Dimethylpropionic Acid as an Imaging Agent for Tumor Detection. Journal of Nuclear Medicine, 2014, 55, 1506-1512.	5.0	22
76	AKT activation controls cell survival in response to HDAC6 inhibition. Cell Death and Disease, 2016, 7, e2286-e2286.	6.3	22
77	Bioorthogonal chemistry for <sup>68</sup> Ga radiolabelling of DOTA-containing compounds. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 291-297.	1.0	21
78	Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. Journal of Nuclear Medicine, 2015, 56, 1855-1861.	5.0	21
79	Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for Pre-phase I positron emission tomography studies in cancer patients. British Journal of Cancer, 2002, 86, 1052-1056.	6.4	20
80	Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget, 2018, 9, 27346-27362.	1.8	20
81	Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine". European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1559-1574.	6.4	19
82	Mn-salen catalysed benzylic C-H activation for the synthesis of aryl [ <sup>18</sup> F]CF <sub>3</sub> -containing PET probes. Chemical Communications, 2015, 51, 8439-8441.	4.1	18
83	Novel Approach to Imaging Active Takayasu Arteritis Using Somatostatin Receptor Positron Emission Tomography/Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2020, 13, e010389.	2.6	18
84	2-Substituted-2,3-dihydro-1H-quinolin-4-ones via Acid-Catalyzed Tandem Rupe Rearrangement-Donnelly-Farrell Ring Closure of 2-(3-Hydroxypropynyl)anilines. Synlett, 2011, 2011, 241-244.	1.8	17
85	Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. Physics in Medicine and Biology, 2012, 57, 3419-3433.	3.0	17
86	Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. European Radiology, 2012, 22, 1465-1478.	4.5	17
87	Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer. Journal of Clinical Pathology, 2015, 68, 703-709.	2.0	17
88	3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. Molecular Cancer Therapeutics, 2019, 18, 376-388.	4.1	17
89	Use of radioiodine in nuclear medicine: A brief overview. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 92-108.	1.0	17
90	A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and validation of multivariable clinical prediction models. EBioMedicine, 2022, 77, 103911.	6.1	17

#	ARTICLE	IF	CITATIONS
91	Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC). <i>British Journal of Cancer</i> , 2022, 126, 1047-1054.	6.4	17
92	Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. <i>Nuclear Medicine and Biology</i> , 2012, 39, 652-665.	0.6	16
93	Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors. <i>MedChemComm</i> , 2013, 4, 693.	3.4	16
94	Small Organ Segmentation in Whole-Body MRI Using a Two-Stage FCN and Weighting Schemes. <i>Lecture Notes in Computer Science</i> , 2018, , 346-354.	1.3	16
95	Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals. <i>Molecular Pharmaceutics</i> , 2020, 17, 2245-2259.	4.6	15
96	Radiopharmaceuticals as probes to characterize tumour tissue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 537-561.	6.4	14
97	Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. <i>British Journal of Pharmacology</i> , 2019, 176, 3712-3722.	5.4	14
98	PET Imaging of Steroid Hormone Receptor Expression. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00026.	1.4	13
99	Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics. <i>ChemNanoMat</i> , 2018, 4, 361-372.	2.8	13
100	Development of <sup>68</sup> Ga-labelled ultrasound microbubbles for whole-body PET imaging. <i>Chemical Science</i> , 2019, 10, 5603-5615.	7.4	13
101	[ <sup>18</sup> F]FET- <sup>125</sup> I-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide. <i>Cancers</i> , 2020, 12, 865.	3.7	13
102	The application of radiomics in laryngeal cancer. <i>British Journal of Radiology</i> , 2021, 94, 20210499.	2.2	13
103	Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 1286-1293.	6.4	13
104	Luciferase fragment complementation imaging in preclinical cancer studies. <i>Oncoscience</i> , 2014, 1, 310-325.	2.2	13
105	Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ([ <sup>124</sup> I]-SHPP) and its use for labelling a VEGF antibody as a PET tracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 1077-1090.	1.0	12
106	<sup>18</sup> F-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4. <i>Journal of Fluorine Chemistry</i> , 2012, 135, 200-206.	1.7	12
107	Design and synthesis of novel <sup>18</sup> F-radiolabelled glucosamine derivatives for cancer imaging. <i>MedChemComm</i> , 2013, 4, 653.	3.4	12
108	Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. <i>Oncogene</i> , 2015, 34, 4439-4447.	5.9	12

#	ARTICLE	IF	CITATIONS
109	[ <sup>18</sup> F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1239-1251.	6.4	12
110	The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 1570-1579.	7.0	12
111	Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. <i>Anti-cancer Drug Design</i> , 1998, 13, 703-30.	0.3	12
112	Repeatability of quantitative <sup>18</sup> F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 951-961.	6.4	11
113	Reliability of dynamic contrast-enhanced magnetic resonance imaging data in primary brain tumours: a comparison of Tofts and shutter speed models. <i>Neuroradiology</i> , 2019, 61, 1375-1386.	2.2	11
114	An improved automated radiosynthesis of [ <sup>18</sup> F]FET- <sup>125</sup> I-AG-TOCA. <i>Reaction Chemistry and Engineering</i> , 2019, 4, 569-574.	3.7	11
115	3-D Microvascular Imaging Using High Frame Rate Ultrasound and ASAP Without Contrast Agents: Development and Initial <i>In Vivo</i> Evaluation on Nontumor and Tumor Models. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2019, 66, 939-948.	3.0	11
116	Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers. <i>British Journal of Cancer</i> , 2021, 125, 1462-1465.	6.4	11
117	The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture. <i>British Journal of Radiology</i> , 2010, 83, 814-822.	2.2	10
118	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. , 2021, 9, e001519.		10
119	Synthesis of [ <sup>18</sup> F]fluoro-pivalic acid: an improved PET imaging probe for the fatty acid synthesis pathway in tumours. <i>MedChemComm</i> , 2013, 4, 1350.	3.4	9
120	Scavenging strategy for specific activity improvement: application to a new CXCR4-specific cyclopentapeptide positron emission tomography tracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 679-685.	1.0	9
121	Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. <i>EJNMMI Research</i> , 2019, 9, 18.	2.5	9
122	One-Pot Radiosynthesis and Biological Evaluation of a Caspase-3 Selective 5-[ <sup>123</sup> I, <sup>125</sup> I]iodo-1,2,3-triazole derived Isatin SPECT Tracer. <i>Scientific Reports</i> , 2019, 9, 19299.	3.3	9
123	Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [ <sup>18</sup> F]fluoromethyl-(1,2- <sup>2</sup> H <sub>4</sub> )-choline. <i>Theranostics</i> , 2020, 10, 8677-8690.	10.0	9
124	Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using <sup>18</sup> F-Fluorothymidine PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1743-1748.	5.0	9
125	Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: A <sup>31</sup> P magnetic resonance spectroscopy study. <i>Radiation Oncology Investigations</i> , 1998, 6, 249-254.	0.9	8
126	Design, synthesis and initial characterisation of a radiolabelled [ <sup>18</sup> F]pyrimidoindolone probe for detecting activated caspase-3/7. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 5418-5423.	2.8	8



#	ARTICLE	IF	CITATIONS
127	Synthesis and pre-clinical evaluation of a [ <sup>18</sup> F]fluoromethyl-tanaproget derivative for imaging of progesterone receptor expression. RSC Advances, 2016, 6, 57569-57579.	3.6	8
128	Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using <sup>18</sup> F-ICMT-11 and <sup>18</sup> F-FLT PET. Journal of Nuclear Medicine, 2018, 59, 1558-1565.	5.0	8
129	Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965. Cancers, 2020, 12, 1703.	3.7	8
130	Radiolabelling an <sup>18</sup> F biologic via facile IEDDA click chemistry on the GE FASTLab, a platform. Reaction Chemistry and Engineering, 2021, 6, 1070-1078.	3.7	8
131	Correction of Fat-Water Swaps in Dixon MRI. Lecture Notes in Computer Science, 2016, , 536-543.	1.3	8
132	Evaluation of lactate as a <sup>1</sup> H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiation Research, 1998, 150, 38-42.	1.5	8
133	Iodo Silanes as Superior Substrates for the Solid Phase Synthesis of Molecularly Imprinted Polymer Nanoparticles. Polymers, 2022, 14, 1595.	4.5	8
134	Iodination of terminal alkynes using KI/CuSO <sub>4</sub> – A facile method with potential for radio-iodination. Tetrahedron Letters, 2019, 60, 936-939.	1.4	7
135	Development of a fluorine-18 radiolabelled fluorescent chalcone: evaluated for detecting glycogen. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 17.	3.9	7
136	Integrating the OHIF Viewer into XNAT: Achievements, Challenges and Prospects for Quantitative Imaging Studies. Tomography, 2022, 8, 497-512.	1.8	7
137	Development of a multi-task learning V-Net for pulmonary lobar segmentation on CT and application to diseased lungs. Clinical Radiology, 2022, 77, e620-e627.	1.1	7
138	Clinical Translation of Molecular Imaging Agents Used in PET Studies of Cancer. Advances in Cancer Research, 2014, 124, 329-374.	5.0	6
139	Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results. Clinical Radiology, 2018, 73, 832.e9-832.e16.	1.1	6
140	Solid-supported cyanoborohydride cartridges for automation of reductive amination radiochemistry. Reaction Chemistry and Engineering, 2019, 4, 1748-1751.	3.7	6
141	Clinical translation of <sup>18</sup> F-fluoropivalate – a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2549-2561.	6.4	6
142	Caspase-Based PET for Evaluating Pro-Apoptotic Treatments in a Tuberculosis Mouse Model. Molecular Imaging and Biology, 2020, 22, 1489-1494.	2.6	6
143	Fully automated deep-learning section-based muscle segmentation from CT images for sarcopenia assessment. Clinical Radiology, 2022, 77, e363-e371.	1.1	6
144	Imaging as a pharmacodynamic and response biomarker in cancer. Clinical and Translational Imaging, 2014, 2, 13-31.	2.1	5

#	ARTICLE	IF	CITATIONS
145	Effective Detection and Monitoring of Glioma Using [18F]FPIA PET Imaging. <i>Biomedicines</i> , 2021, 9, 811.	3.2	5
146	Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics. <i>Pharmaceutics</i> , 2021, 13, 1246.	4.5	5
147	<sup>2</sup> -Deoxy- <sup>2</sup> , <sup>2</sup> -difluorothymidine analogues for radiolabeling with fluorine-18 and other biomedical applications. <i>Tetrahedron Letters</i> , 2015, 56, 3293-3297.	1.4	4
148	Baseline and longitudinal variability of normal tissue uptake values of [18F]-fluorothymidine-PET images. <i>Nuclear Medicine and Biology</i> , 2017, 51, 18-24.	0.6	4
149	Detecting hypoxia <i>in vitro</i> using <sup>18</sup> F-pretargeted IEDDA <i>click</i> -chemistry in live cells. <i>RSC Advances</i> , 2021, 11, 20335-20341.	3.6	4
150	Phosphorylation Status of Thymidine Kinase 1 Following Antiproliferative Drug Treatment Mediates <sup>3</sup> -Deoxy- <sup>3</sup> -[18F]-Fluorothymidine Cellular Retention. <i>PLoS ONE</i> , 2014, 9, e101366.	2.5	4
151	Imaging in drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 902-4.	0.3	4
152	Towards an MMP-2-activated molecular agent for cancer imaging. <i>Dalton Transactions</i> , 2018, 47, 1530-1534.	3.3	3
153	Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2009-2023.	6.4	3
154	A kit-based aluminium- <sup>18</sup> F]fluoride approach to radiolabelled microbubbles. <i>Chemical Communications</i> , 2021, 57, 11677-11680.	4.1	3
155	Direct incorporation of [18F] into Aliphatic Systems: A promising Mn-catalysed Labelling Technique for PET Imaging. <i>Current Radiopharmaceuticals</i> , 2021, 14, 101-106.	0.8	3
156	Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker. <i>Oncotarget</i> , 2010, 1, 163-6.	1.8	3
157	A multifractal approach to space-filling recovery for PET quantification. <i>Medical Physics</i> , 2014, 41, 112505.	3.0	2
158	Metabolically active tumour volume segmentation from dynamic [18F]FLT PET studies in non-small cell lung cancer. <i>EJNMMI Research</i> , 2015, 5, 26.	2.5	2
159	Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. <i>PLoS ONE</i> , 2016, 11, e0161427.	2.5	2
160	Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. <i>EJNMMI Research</i> , 2016, 6, 81.	2.5	2
161	Multi-frame rate plane wave contrast-enhanced ultrasound imaging for tumour vascular imaging and perfusion quantification. , 2017, , .		2
162	Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019. <i>Pharmaceutics</i> , 2021, 13, 1078.	4.5	2

#	ARTICLE	IF	CITATIONS
163	68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs).. Journal of Clinical Oncology, 2017, 35, 4093-4093.	1.6	2
164	Variational Bayes for high-dimensional proportional hazards models with applications within gene expression. Bioinformatics, 2022, 38, 3918-3926.	4.1	2
165	Functional imaging of hepatocellular carcinoma. Hepatic Oncology, 2016, 3, 137-153.	4.2	1
166	Contrast vs Non-Contrast Enhanced Microvascular Imaging Using Acoustic Sub-Aperture Processing (ASAP): In Vivo Demonstration. , 2018, , .		1
167	High-Contrast 3D in Vivo Microvascular Imaging Using Scanning 2D Ultrasound and Acoustic Sub-Aperture Processing (ASAP). , 2018, , .		1
168	Synthesis and evaluation of 3- <sup>18</sup> F-fluorothymidine-5-squaryl as a bioisostere of 3- <sup>18</sup> F-fluorothymidine-5-monophosphate. RSC Advances, 2021, 11, 12423-12433.	3.6	1
169	Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: A 31P nuclear magnetic resonance study in vivo and in vitro. Magnetic Resonance in Medicine, 1999, 41, 897-903.	3.0	1
170	Design and Development of Probes for In vivo Molecular and Functional Imaging of Cancer and Cancer Therapies by Positron Emission Tomography (PET). , 0, , 1243-1270.		1
171	Abstract 4235: Choline metabolism is an early predictor of EGFR-mediated survival in NSCLC. Cancer Research, 2016, 76, 4235-4235.	0.9	1
172	Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach. PLoS ONE, 2021, 16, e0260186.	2.5	1
173	Multi-frame rate plane wave contrast-enhance ultrasound imaging for tumour vasculature imaging and perfusion quantification. , 2017, , .		0
174	Resistance to tyrosine kinase-targeted therapy in lung cancer: Autophagy and metabolic changes. Meta Gene, 2018, 17, S10.	0.6	0
175	Reliability of DCE MRI data in primary brain tumours: a comparison of Tofts and Shutter Speed Models. Neuro-Oncology, 2019, 21, iv11-iv11.	1.2	0
176	IMAGING OF PHARMACODYNAMIC END POINTS IN CLINICAL TRIALS. , 2006, , 299-336.		0
177	Abstract A222: Assessment of tumor response to therapy with the caspase-3/7 specific [18F]ICMT-1 PET imaging tracer. , 2009, , .		0
178	Abstract 5274: Noninvasive early assessment of tumor response to the SMAC mimetic TL32711 with a caspase-3/7-specific PET imaging radiotracer. , 2011, , .		0
179	Abstract 2660: Regulation of 18F-fluorothymidine uptake by thymidine kinase 1 protein phosphorylation.. , 2013, , .		0
180	Abstract A15: HDAC6 inhibitor C1A abrogates the recruitment of the autophagic machinery and synergizes with proteasome, src kinase, and PI3K-mTOR inhibition.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
181	Abstract B140: Positron emission tomography imaging of HER2 expression and pharmacodynamic response to HSP90 inhibition with the next-generation ZHER2:2891 Affibody molecule [18F]GE-226., 2013, , .		0
182	Abstract P5-01-02: Evaluation of apoptosis in breast cancer using the novel PET probe [18F]ICMT-11 in patients treated with neoadjuvant FEC chemotherapy: Initial assessment of optimum imaging time and relation to caspase-3 immunostaining. , 2015, , .		0